Detect and Infer the Severity of COPD by Intelligent Terminal Device

Overview

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases. Early detection and treatment are critical to prevent the deterioration of COPD. In this study, we aim to develop an algorithm that can detect and infer the severity level of COPD from physiological parameters and audio data which are collected by a wearable device. We will complete the study in two stages: stage 1. A panel study to assess the ability to infer the severity of COPD by intelligent terminal devices; stage 2. Establish an algorithm that can detect and infer the severity level of COPD by intelligent terminal devices.

Full Title of Study: “Establishment of an Algorithm That Can Detect and Infer the Severity Level of COPD by Intelligent Terminal Device”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: March 31, 2023

Detailed Description

In this study, we aim to establish an algorithm that can detect and infer the severity level of COPD from physiological parameters, coughing sounds, and forceful blowing sounds data that are collected by wearable devices. This study is divided into two stages. Stage one: A panel study to assess the ability to infer the severity of COPD by intelligent terminal devices. 30 patients with stable COPD will be enrolled and will undergo pulmonary function tests, electrocardiogram, echocardiography measurement, blood gas analysis, six-minutes walking test (6MWT), and polysomnography. And they are required to fill in the questionnaires related to COPD every day. Physiological parameters including oxygen saturation, heart rate, sleep, and physical activity will be collected by a wearable device for 7-14 consecutive days. Coughing and forceful blowing sounds will be collected twice daily. The association between the severity of COPD and physiological parameters from the wearable device will be analyzed. Stage two: Establish an algorithm that can detect and infer the severity level of COPD by intelligent terminal devices. 200 patients with stable COPD and 200 non- COPD subjects will be enrolled. Questionnaires related to COPD will be collected, and subjects will undergo pulmonary function tests and electrocardiograms. Physiological parameters including oxygen saturation and heart rate will be continuously collected by a wearable device for about 3～7 days. We will also collect coughing and forceful blowing sounds. A COPD diagnosis algorithm model based on physiological parameters and audio data of intelligent terminal devices will be established. The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2022-083). Any protocol modifications will be submitted for IRB review and approval.

Arms, Groups and Cohorts

• Patients with stable COPD in Stage1
  • no intervention
• Patients with stable COPD in Stage2
  • no intervention
• Non-COPD subjects in Stage2
  • no intervention

Clinical Trial Outcome Measures

Primary Measures

• Stage 1: Association between the severity of COPD airflow restriction and data collected by wearable devices
  • Time Frame: 2 months
• Stage 2：Establish an algorithm that can detect and infer the severity level of COPD by intelligent terminal devices
  • Time Frame: 5 months

Secondary Measures

• Stage 1: The compliance of subjects with wearable devices
  • Time Frame: 2 months
• Stage 1: Association between the severity of COPD airflow restriction, CAT score, mMRC score, echocardiography, blood gas analysis, six-minutes walking distance, polysomnography，and data collected by wearable devices
  • Time Frame: 2 months
• Stage 2: Association between the severity of COPD airflow restriction, CAT score, mMRC score，and data collected by wearable devices
  • Time Frame: 5 months
• Stage 2: number of adverse events
  • Time Frame: 5 months

Participating in This Clinical Trial

Stage 1: Inclusion criteria:

1. Older than 18 years old, no gender limitation; 2. In COPD stable stage (if there is an acute exacerbation, patients should be enrolled 3 months after remission of the exacerbation); 3. Be able to carry out daily activities and wear wearable devices; 4. Have willing to participate in this study and comply with the study protocol, and can sign informed consent; 5. Possess mobile communication equipment, which can meet the requirement of installing wearable device APP, and have a recording function. Exclusion criteria:

1. Have been diagnosed with chronic respiratory diseases other than COPD, such as bronchial asthma, lung cancer, active tuberculosis, bronchiectasis, and diffuse lung diseases (interstitial pneumonia, occupational lung disease, sarcoidosis, etc.); 2. lobectomy and/or lung transplantation, pleural disease; 3. Complicated with serious underlying diseases, including severe mental illness, intellectually impaired diseases, neurological disease (resulting in limb movement disorder), malignant tumor (PS score > 2), chronic liver disease (transaminase > Normal high limit 3 times), heart failure (NYHA> Grade 3), autoimmune disease, chronic kidney disease (CKD-5), unstable coronary heart disease, arrhythmias (atrial fibrillation, atrial flutter, severe ventricular arrhythmia), congenital heart disease, pulmonary hypertension, etc., or life expectancy of less than 6 months; 4. Malnutrition (BMI<18 kg/m2); 5. Bilateral wrist and hand edema, wrist soft tissue injury, can not wear a watch/bracelet because of the incompleted skin; 6. Double upper limb pigmentation or abnormal blood supply (occlusion, thrombosis, trauma, etc.) Stage 2 COPD group: Patients with stable COPD（same inclusion and exclusion criteria as Stage 1） Control group: healthy non-COPD population whose lung function must meet: FEV1/ FVC > 0.7, FEV1 > Pred 80% after bronchial dilation test when they are enrolled; Inclusion criteria:

1. Older than 18 years old; 2. Be able to carry out daily activities and wear wearable devices; 3. Have willing to participate in this study and comply with the study protocol, and can sign informed consent; 4. Possess mobile communication devices, which can meet the requirements of installing wearable devices APP, and have a recording function. Exclusion criteria:

COPD and other serious chronic diseases (same exclusion criteria as COPD group).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Peking University First Hospital
• Collaborator
  • People’s Hospital of Beijing Daxing District
• Provider of Information About this Clinical Study
  • Principal Investigator: Guangfa Wang, Prof. & MD. – Peking University First Hospital
• Overall Official(s)
  • Guangfa Wang, MD, Study Chair, Peking University First Hospital